JSPR JASPER THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, JASPER THERAPEUTICS INC reported revenue of n/a, net income of −$2.76M and diluted EPS of −$0.10; for the fiscal year ended December 2025 revenue was n/a.
JSPR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$83.9M, net income −$76 (margin n/a), EPS −$3.95
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$76.2M, net income −$71.3M (margin n/a), EPS −$4.89
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$68.9M, net income −$64.5M (margin n/a), EPS −$6.18
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$51.2M, net income −$37.7M (margin n/a), EPS −$10.33
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$36.8M, net income −$30.6M (margin n/a), EPS −$2.69
JSPR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.76M, EPS −$0.10
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.17M, EPS −$0.04
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $66.7M, EPS $0.33
- Quarter ended Sep 30, 2025: revenue n/a, net income −$18.7M, EPS −$1.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.7M, EPS −$1.74
- Quarter ended Mar 31, 2025: revenue n/a, net income −$21.2M, EPS −$1.41
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$24.4M, EPS −$1.65
- Quarter ended Sep 30, 2024: revenue n/a, net income −$18.6M, EPS −$1.24
- Quarter ended Jun 30, 2024: revenue n/a, net income −$14.6M, EPS −$0.97
- Quarter ended Mar 31, 2024: revenue n/a, net income −$13.7M, EPS −$1.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$16.6M, EPS −$1.49
- Quarter ended Sep 30, 2023: revenue n/a, net income −$17.5M, EPS −$1.60
- Quarter ended Jun 30, 2023: revenue n/a, net income −$16.1M, EPS −$1.47
- Quarter ended Mar 31, 2023: revenue n/a, net income −$14.3M, EPS −$1.62
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$13.2M, EPS −$9.66
- Quarter ended Sep 30, 2022: revenue n/a, net income −$11.9M, EPS −$0.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.4M, EPS −$0.29
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.21M, EPS −$0.06
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.06M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.41M, EPS −$0.69
JSPR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$77.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$62.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$52.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$45.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$33.7M, share buybacks n/a
JSPR balance sheet
- Jun 30, 2026: cash $7.31M, total assets $11.8M, total liabilities $10.4M, shareholders' equity $1.41M
- Mar 31, 2026: cash $14.1M, total assets $21.2M, total liabilities $17.8M, shareholders' equity $3.40M
- Dec 31, 2025: cash $28.7M, total assets $35.8M, total liabilities $31.6M, shareholders' equity $4.15M
- Sep 30, 2025: cash $50.9M, total assets $57.5M, total liabilities $45.9M, shareholders' equity $11.6M
- Jun 30, 2025: cash $39.5M, total assets $46.5M, total liabilities $23.0M, shareholders' equity $23.5M
- Mar 31, 2025: cash $48.8M, total assets $57.6M, total liabilities $15.4M, shareholders' equity $42.2M
- Dec 31, 2024: cash $71.6M, total assets $79.9M, total liabilities $18.2M, shareholders' equity $61.7M
- Sep 30, 2024: cash $92.5M, total assets $99.4M, total liabilities $15.7M, shareholders' equity $83.7M
Is JSPR profitable?
Yes. JASPER THERAPEUTICS INC earned $44.0M over the last four quarters.
What is JSPR's EPS?
Diluted earnings per share over the last four quarters were −$0.94; −$0.10 in the latest quarter.